BSX Q4 sales $3.73B (+14.9% reported), adj EPS $0.55; FY2024 adj EPS guidance $2.23-$2.27

BOSTON SCIENTIFIC CORP

2023-FY EPS reported $1.07 revenue$14,240,000,000

Q4 net sales $3.725B (+14.9% reported); GAAP EPS $0.34, adj EPS $0.55 beat guidance ranges.
FY2023 net sales $14.240B (+12.3% reported); GAAP EPS $1.07; adj EPS $2.05 versus $1.71 prior year.
FY2024 guidance: reported sales growth 8.5-9.5%; GAAP EPS $1.38-$1.42; adj EPS $2.23-$2.27.
FDA approved FARAPULSE PFA System for paroxysmal atrial fibrillation; enrollment in AVANT GUARD trial commenced.
Agreed to acquire Axonics (AXNX) for urinary/bowel dysfunction treatment; Relievant Medsystems acquisition completed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.8

BOSTON SCIENTIFIC CORP reported financial results for the fourth quarter and full year ended December 31, 2023.

Period: the fourth quarter and full year ended December 31, 2023
Result: reported results

Exact text from the filing

On January 31, 2024, Boston Scientific Corporation issued a press release announcing financial results for the fourth quarter and full year ended December 31, 2023.

View on SEC.gov

3 earnings releases filed in the last 30 days. Browse all earnings releases →

BOSTON SCIENTIFIC CORP filing history →

Source: SEC EDGAR

accession 0000885725-24-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.